ArticleClinical cancer research : an official journal of the American Association for Cancer Research2014
Blocking immunosuppressive checkpoints for glioma therapy: the more the Merrier!
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma.Journal of neuro-oncology · 2018Trial
- Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.Frontiers in immunology · 2018Trial
- Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma.Cancer immunology, immunotherapy : CII · 2016Trial
- Local controlled release of stabilized monoclonal antibodies.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Overcoming immune evasion with innovative multi-target approaches for glioblastoma.Frontiers in immunology · 2025Review
- Elevated TAF12 Expression Predicts Poor Prognosis in Glioma Patients: Evidence from Bioinformatic and Immunohistochemical Analyses.Biomolecules · 2022Article
- Research Progress About Glioma Stem Cells in the Immune Microenvironment of Glioma.Frontiers in pharmacology · 2021Review
- TLR3 regulates PD-L1 expression in human cytomegalovirus infected glioblastoma.International journal of clinical and experimental pathology · 2018Article
- Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma.Frontiers in immunology · 2018Review
- Targeting immune checkpoints in malignant glioma.Oncotarget · 2017Review
- Convection-enhanced Delivery of Therapeutics for Malignant Gliomas.Neurologia medico-chirurgica · 2017Review
- Recent advances and future of immunotherapy for glioblastoma.Expert opinion on biological therapy · 2016Review
- Focused ultrasound-aided immunomodulation in glioblastoma multiforme: a therapeutic concept.Journal of therapeutic ultrasound · 2016Review
- Circulating biomarkers for gliomas.Nature reviews. Neurology · 2015Review
- FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.Journal of the National Cancer Institute · 2015Article
- Targeting the indoleamine 2,3-dioxygenase pathway in cancer.Journal for immunotherapy of cancer · 2015Review
- Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites.Frontiers in oncology · 2015Review
- Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity.Oncoimmunology · 2014Review
- Novel anti-melanoma treatment: focus on immunotherapy.Chinese journal of cancer · 2014Article
- Targeting the Siglec/sialic-acid axis in glioblastoma: Glycome-mediated immune evasion and emerging therapeutic platforms.Neuro-oncology advancesReview
Corrections and comments
- Comment on
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Immunosuppressive checkpoints mediated by IDO, CTLA4, and PD1/PDL1 play a critical role in glioma progression and the efficacy of immunotherapies. Combined blockade of these immunosuppressive checkpoints in a glioma model elicited long-term survival. This combined blockade adds to the armamentarium of anti-glioma therapies, which could be implemented in clinical trials. Clin Cancer Res; 20(20); 5147-9. ©2014 AACR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.